Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up-Reference-Cited by-同舟云学术

Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up

Published:2020-07-23 Issue:2 Volume:100 Page:595-599
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Shahswar Rabia^ORCID,Beutel Gernot,Gabdoulline Razif,Koenecke Christian,Markel Dominik,Eder Matthias,Stadler Michael,Gohring Gudrun,Schlegelberger Brigitte,Trummer Arne,Krauter Juergen,Thol Felicitas,Heuser Michael

Funder

DFG

European Union's Horizon 2020 research and innovation program

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04181-5.pdf

Reference10 articles.

1. Bhola PD, Letai A (2016) Mitochondria-judges and executioners of cell death sentences. Mol Cell 61(5):695–704. https://doi.org/10.1016/j.molcel.2016.02.019

2. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A (2016) Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukaemia. Cancer Discov 6(10):1106–1117.4. https://doi.org/10.1158/2159-8290.CD-16-0313

3. Wei AH et al (2020) Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood. https://doi.org/10.1182/blood.2020004856

4. DiNardo CD et al (2019) Venetoclax combined with Decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7–17. https://doi.org/10.1182/blood-2018-08-868752

5. Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C (2020) Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol S0923-7534(20):36079–36078. https://doi.org/10.1016/j.annonc.2020.02.018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax combined with decitabine induced tumor lysis syndrome in a young patient with acute myeloid leukemia: a case report and literature review;Anti-Cancer Drugs;2024-02-23

2. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up;Leukemia & Lymphoma;2023-11-06

3. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia;Leukemia Research;2022-06

4. DOPAMINE ACTIVATES ACUTE MYELOID LEUKAEMIA NLRP3 INFLAMMASOME THROUGH THE DR5 RECEPTOR PATHWAY TO PROMOTE CANCER AND INDUCE CHEMOTHERAPY RESISTANCE;ACTA MEDICA MEDITERR;2022

5. Impact of Oncology Pharmacists on the Knowledge, Attitude, and Practices of Clinicians to Enhance Patient Engagement of Self-Administered Oral Oncolytics;Pharmacy;2021-07-23